人體生長荷爾蒙市場規模、佔有率和成長分析（按產品、應用、通路和地區分類）－2026-2033年產業預測

預計到 2024 年，全球人體生長荷爾蒙市場規模將達到 71 億美元，到 2025 年將達到 79.7 億美元，到 2033 年將達到 201.7 億美元，在預測期（2026-2033 年）內，複合年成長率為 12.3%。

全球人體生長荷爾蒙市場持續穩定成長，主要得益於生長激素缺乏症治療臨床指引的進步以及重組荷爾蒙療法的創新。治療途徑的改善和人們對生長激素缺乏症認知的提高進一步推動了這一成長。各國政府和衛生組織正透過宣傳活動促進早期發現，並強調解決此疾病的重要性。順應新興市場趨勢，主要企業正加大研發投入，致力於開發副作用較少的生長激素。此外，人體生長荷爾蒙在組織再生和細胞分裂等過程中發揮著至關重要的作用，凸顯了其在人類整體生長和健康中的重要性，因此各方正齊心協力，努力有效治療激素相關疾病。

全球人體生長荷爾蒙市場促進因素

透納氏症和生長激素缺乏症等異常生長模式的發生率不斷上升，顯著影響全球對人體生長荷爾蒙產品的需求。隨著人們對這些疾病的認知不斷提高，早期診斷也日益普及，進一步增加了對有效治療的需求。這一趨勢，加上醫療保健服務水準的提高，正推動全球人體生長荷爾蒙市場持續擴張。此外，醫護人員和大眾對相關知識的普及也促使人們認知到解決這些生長遲緩的重要性，最終使荷爾蒙補充療法得到更廣泛的應用。

限制全球人體生長荷爾蒙市場的因素

由於有其他治療生長遲緩的替代療法，全球人體生長荷爾蒙市場面臨挑戰。非荷爾蒙療法和生活方式調整提供了可行的選擇，無需荷爾蒙干預即可達到類似的效果。因此，患者和醫療保健提供者可能更傾向於這些創傷性較小、價格通常更實惠的替代療法。這種偏好的轉變限制了對生長激素療法的需求，並抑制了市場的成長潛力。因此，各種治療方法的出現促使人們更加謹慎地使用生長激素，這成為市場格局中的一個主要阻礙因素。

全球人體生長荷爾蒙市場趨勢

全球人體生長荷爾蒙市場正日益擁抱個人化治療方案，這反映​​出個人化給藥和給藥技術的顯著趨勢。生物技術的進步使醫療專業人員能夠根據患者的特定需求量身定做荷爾蒙療法，從而最佳化治療效果並改善患者的整體體驗。這種個人化轉變不僅提高了療效，也有助於增強患者對治療通訊協定的依從性。因此，在消費者對能夠應對不同生理特徵和獨特健康挑戰的個人化醫療解決方案的需求不斷成長的推動下，該市場呈現出成長跡象，並有望最終改變荷爾蒙療法的格局。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球人體生長荷爾蒙市場規模（按產品和複合年成長率分類）（2026-2033 年）

• 長效
• 其他

全球人體生長荷爾蒙市場規模（按應用及複合年成長率分類）（2026-2033 年）

• 生長激素（GH）缺乏症
• 成人生長激素缺乏症
• 兒童生長激素缺乏症
• 透納氏症
• 原發性矮小症
• 普拉德-威利症候群
• 胎齡偏矮
• 其他

全球人體生長荷爾蒙市場規模（按分銷管道和複合年成長率分類）（2026-2033 年）

• 醫院藥房
• 零售藥房
• 網路藥房
• 專科藥房

全球人體生長荷爾蒙市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Novo Nordisk A/S（Denmark）
• Pfizer Inc.（USA）
• Eli Lilly and Company（USA）
• Merck KGaA（Germany）
• Genentech Inc.（USA）（Note：Part of the Roche Group）
• Ipsen SA（France）
• Ferring Pharmaceuticals（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sandoz International GmbH（Germany）（Part of Novartis AG）
• Anhui Anke Biotechnology（Group）Co., Ltd.（China）
• GeneScience Pharmaceuticals Co., Ltd.（China）
• OPKO Health, Inc.（USA）
• Ascendis Pharma A/S（Denmark）
• EMD Serono Inc.（USA）（Part of Merck KGaA）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Strongbridge Biopharma（USA）
• LG Life Sciences（South Korea）
• Biopartners GmbH（Germany）

結論與建議

Global Human Growth Hormone Market size was valued at USD 7.1 Billion in 2024 and is poised to grow from USD 7.97 Billion in 2025 to USD 20.17 Billion by 2033, growing at a CAGR of 12.3% during the forecast period (2026-2033).

The global human growth hormone market is experiencing robust expansion, driven by advancements in clinical guidelines for treating growth hormone deficiency and innovations in recombinant hormone therapies. Increased accessibility to treatments and heightened awareness of growth hormone insufficiency further propel this growth. Governments and health organizations promote early detection through awareness initiatives, underscoring the importance of addressing this condition. Major companies globally are investing in research and development to create growth hormones with fewer side effects, aligning with emerging market trends. Additionally, there is a concerted effort to effectively treat hormone-related conditions, as human growth hormone plays a vital role in processes like tissue regeneration and cell division, underscoring its significance in overall human growth and health management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Human Growth Hormone market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Human Growth Hormone Market Segments Analysis

Global Human Growth Hormone Market is segmented by Product, Application, Distribution Channel and region. Based on Product, the market is segmented into Long Acting and Others. Based on Application, the market is segmented into Growth Hormone (GH) Deficiency, Adult GH Deficiency, Pediatric GH Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small For Gestational Age and Other. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy,Online Pharmacyand Specialty Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Human Growth Hormone Market

The rising incidence of irregular growth patterns, including conditions like Turner syndrome and growth hormone deficiency, significantly influences the global demand for human growth hormone products. As awareness of these conditions increases, earlier diagnosis becomes more common, thereby escalating the need for effective treatments. This trend, combined with improved healthcare access and services, further propels the expansion of the global human growth hormone market. Enhanced education among healthcare professionals and the public also contribute to recognizing the importance of addressing these growth disorders, ultimately leading to a greater emphasis on hormone replacement therapies.

Restraints in the Global Human Growth Hormone Market

The Global Human Growth Hormone market faces challenges due to the presence of alternative treatments for growth disorders. Non-hormonal therapies and lifestyle modifications offer viable options that may provide similar benefits without the need for hormone intervention. As a result, both patients and healthcare providers may prefer these less invasive and often more affordable alternatives. This shift in preference limits the demand for HGH therapies, hindering the growth potential of the market. Consequently, the emergence of various treatment modalities encourages a more cautious approach to HGH usage, creating a significant restraint in the overall market landscape.

Market Trends of the Global Human Growth Hormone Market

The global human growth hormone market is increasingly embracing personalized treatment approaches, reflecting a significant trend towards individualized dosing and delivery techniques. Advancements in biotechnology enable healthcare professionals to tailor growth hormone therapies to meet the specific needs of patients, optimizing therapeutic outcomes while enhancing the overall patient experience. This shift towards customization not only improves efficacy but also fosters stronger patient adherence to treatment protocols. As a result, the market is poised for growth, driven by the rising consumer demand for personalized healthcare solutions that cater to diverse physiological profiles and unique health challenges, ultimately transforming the landscape of growth hormone therapy.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Human Growth Hormone Market Size by Product & CAGR (2026-2033)

• Market Overview
• Long Acting
• Others

Global Human Growth Hormone Market Size by Application & CAGR (2026-2033)

• Market Overview
• Growth Hormone (GH) Deficiency
• Adult GH Deficiency
• Pediatric GH Deficiency
• Turner Syndrome
• Idiopathic Short Stature
• Prader-Willi Syndrome
• Small For Gestational Age
• Other

Global Human Growth Hormone Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Specialty Pharmacy

Global Human Growth Hormone Market Size & CAGR (2026-2033)

• North America (Product, Application, Distribution Channel)
  • US
  • Canada
• Europe (Product, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech Inc. (USA) (Note: Part of the Roche Group)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Germany) (Part of Novartis AG)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anhui Anke Biotechnology (Group) Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneScience Pharmaceuticals Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OPKO Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ascendis Pharma A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EMD Serono Inc. (USA) (Part of Merck KGaA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Strongbridge Biopharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LG Life Sciences (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biopartners GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations